AKOUOS INC (AKUS) Stock Price & Overview
NASDAQ:AKUS • US00973J1016
The current stock price of AKUS is 13.29 USD. Today AKUS is up by 1.06%. In the past month the price increased by 1.22%. In the past year, price increased by 70.17%.
AKUS Key Statistics
- Market Cap
- 491.015M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.62
- Dividend Yield
- N/A
AKUS Stock Performance
AKUS Stock Chart
AKUS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AKUS. When comparing the yearly performance of all stocks, AKUS is one of the better performing stocks in the market, outperforming 99.76% of all stocks.
AKUS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AKUS. While AKUS has a great health rating, there are worries on its profitability.
AKUS Earnings
AKUS Forecast & Estimates
11 analysts have analysed AKUS and the average price target is 17.68 USD. This implies a price increase of 33.03% is expected in the next year compared to the current price of 13.29.
AKUS Groups
Sector & Classification
AKUS Financial Highlights
Over the last trailing twelve months AKUS reported a non-GAAP Earnings per Share(EPS) of -2.62. The EPS decreased by -20.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.06% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
AKUS Ownership
AKUS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.33 | 406.874B | ||
| AMGN | AMGEN INC | 16.52 | 199.203B | ||
| GILD | GILEAD SCIENCES INC | 16.59 | 178.678B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.77 | 116.013B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.72 | 80.332B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.37 | 42.526B | ||
| INSM | INSMED INC | N/A | 30.205B | ||
| NTRA | NATERA INC | N/A | 28.081B | ||
| BIIB | BIOGEN INC | 11.71 | 27.132B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.72 | 20.958B | ||
| MRNA | MODERNA INC | N/A | 20.742B | ||
| EXAS | EXACT SCIENCES CORP | 341.2 | 19.757B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.5B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AKUS
Company Profile
Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The company is headquartered in Boston, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2020-06-26. The firm is focused on developing precision therapies for forms of sensorineural hearing loss. The firm's genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV), and a novel delivery approach. The firm is focused on executing its initiatives, which include the advancement of its lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of complex etiology, such as AK-antiVEGF for vestibular schwannoma; and development of internal manufacturing capabilities, and a commercial infrastructure.
Company Info
AKOUOS INC
645 Summer Street, Suite 200
Boston MASSACHUSETTS 02210 US
CEO: Emmanuel Simons
Employees: 103
Phone: 18574101818.0
AKOUOS INC / AKUS FAQ
What does AKUS do?
Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The company is headquartered in Boston, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2020-06-26. The firm is focused on developing precision therapies for forms of sensorineural hearing loss. The firm's genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV), and a novel delivery approach. The firm is focused on executing its initiatives, which include the advancement of its lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of complex etiology, such as AK-antiVEGF for vestibular schwannoma; and development of internal manufacturing capabilities, and a commercial infrastructure.
Can you provide the latest stock price for AKOUOS INC?
The current stock price of AKUS is 13.29 USD. The price increased by 1.06% in the last trading session.
Does AKUS stock pay dividends?
AKUS does not pay a dividend.
What is the ChartMill rating of AKOUOS INC stock?
AKUS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is AKOUOS INC (AKUS) stock traded?
AKUS stock is listed on the Nasdaq exchange.
What is the market capitalization of AKUS stock?
AKOUOS INC (AKUS) has a market capitalization of 491.01M USD. This makes AKUS a Small Cap stock.
What is the ownership structure of AKOUOS INC (AKUS)?
You can find the ownership structure of AKOUOS INC (AKUS) on the Ownership tab.